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early stages to metastasis, in particular on regulation of 
energy and lipid metabolism. In addition, her laboratory 
investigates the mechanisms of how obesity impacts 
cancer development. Another research focus is the 
development of curricula to promote research skills in 
interdisciplinary research for both undergraduate and 
graduate students.
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Breast cancer remains the second leading 
cause of cancer death among women in the 
United States, with 99% of breast cancer 
patients surviving fi ve years after diagnosis if 
the tumor is localized. However, if the tumor 
has metastasized, the survival rate decreases to 
22%. Epidemiological and animal studies, as 
well as previous studies from our laboratory 
in in vitro 3D cell culture models, support 
the hypothesis that vitamin D may inhibit 
breast cancer metastasis in humans, but the 
mechanisms remain unknown. The purpose 
of the present studies was to investigate the 
effect of the bioactive vitamin D metabolite, 
1α,25-dihydroxyvitamin D3 (1,25(OH)2D) on 
expression of matrix metalloproteinases 
(MMP) in MCF10CA1a breast epithelial cells. 
MMPs are a family of endopeptidases implicated 
in both cancer cell invasion and migration. First, 
the pattern of MMP expression in MCF10CA1a 
cells was investigated, focusing on MMPs 1,2,3,9 
and 13. MCF10CA1a cells expressed only 
MMP2 mRNA at a detectable level. Treatment 
with 1,25(OH)2D (10 nM,) reduced the expres-
sion of MMP2 by 32%±10 and 35%±7  at 2 
and 5 days, respectively. Furthermore, the 
effect of 1,25(OH)2D on migratory capability 
of MCF10CA1a cells was assessed using 
a wound healing assay. Pretreatment with 
1,25(OH)2D for 48 hours decreased cell migra-
tion by 44%±9.6 relative to vehicle. Overall, 
these studies support a potential role of MMP2 
and migration in 1,25(OH)2D prevention of 
breast cancer metastasis. 
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INTRODUCTION
Breast cancer remains the second leading cause of 
cancer death and is the most frequently diagnosed 
cancer among women, with an expected 40,610 
deaths due to breast cancer and 252,710 new cases 
to be diagnosed in 2017 (American Cancer Society, 
2017). The survival rate of breast cancer patients is 
high, with 99% of patients surviving if the tumor is 
localized. However, if the tumor has metastasized, 
the survival rate decreases to 22% depending on the 
diagnosed stage (American Cancer Society, 2015; 
Yücel, et al., 2014). In addition, studies also show 
70% of patients who are diagnosed with metastatic 
breast cancer at an advanced stage develop bone 
metastasis (Ahn et.al., 2013).
Cancer cells must break down physical barriers, 
including the extracellular matrix and basement mem-
brane, in order for cancer cells to escape the primary 
tumor to a secondary site (thus metastasizing), which 
requires the expression of matrix metalloproteinases 
(MMPs). MMPs are zinc-dependent extracellular 
matrix (ECM) remodeling endopeptidases, which 
have the ability to degrade most components of the 
ECM. There are 26 known MMPs that are highly 
homologous yet differ in their substrate specifi cities. 
Each enzyme has a signal peptide to direct traffi cking 
through the secretory pathway and a well-conserved, 
compact, catalytic domain (Radisky & Radisky, 
2015). Studies show that MMPs are able to modulate 
the tumor microenvironment and regulate signaling 
pathways that control cell growth and migration, the 
immune system, and angiogenesis (Kessenbrock, 
2010). Imbalances in the activity of MMPs can acti-
vate cellular processes that cause DNA damage and 
stimulate genomic instability (Wilmanski, Buhman, 
Donkin, Burgess, & Teegarden, 2017). MMPs may 
also directly induce phenotypic changes associated 
with the epithelial-mesenchymal transition, a develop-
mental process that becomes activated during tumor 
progression (Wilmanski et al., 2017). MMPs could 
stimulate resistance to chemotherapeutics and drive 
tumor progression through proteolytic inactivation of 
the cell death receptor Fas and consequent inhibition 
of the intrinsic apoptosis pathway. Furthermore, 
fi ndings suggest MMP overexpression may indicate 
a higher risk of poor prognosis in breast cancer 
(Ren et al., 2015). 
Evidence suggests that vitamin D may protect 
against breast cancer as well as breast cancer 
metastasis. Vitamin D can be obtained through sun 
exposure, food, and supplements; however, vitamin 
D defi ciency is prevalent in the United States The 
Teegarden laboratory has previously demonstrated 
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RESULTS 
MMPs have been implicated in the processing of 
cytokines, growth factors, and cell adhesion mole-
cules, demonstrating their importance in sustaining 
a cancer cell’s migratory potential. There is also 
evidence that supports MMPs having a role in tumor 
progression and metastasis, in shaping the tumor 
microenvironment, and in driving cancer progression 
and metastasis (Radisky & Radisky, 2015). 
 
In order to study the impact of the active form of 
vitamin D, 1,25(OH)2D, on breast to bone metasta-
sis, a unique 3-D cell model that recapitulates the 
transition steps that occur during breast cancer cell 
metastasis to the bone was utilized (Parikh, Belch, 
Pilarski, & Kirshner, 2014; Parikh, Minser, Rank, 
Glackin, & Kirshner, 2014). In this model system, 
the metastatic cells are plated in matrigel in an upper 
transwell, and the transwell is inserted into a well, 
which contains on the bottom a coating that is similar 
to a bone environment. The cells were treated only  
in the upper well with 1,25(OH)2D, and the number 
of viable cells that implant and grow in the bone ma-
trix was assessed. Using this model, experiments in 
our laboratory showed that the number of viable met-
astatic MCF10CA1a breast cells that successfully me-
tastasized to the bone matrix is drastically decreased 
by 70% with 1,25(OH)2D treatment (Wilmanski et 
al., 2016). In addition, similar results were obtained 
with the metastatic MDA-MB-231 breast cancer cell 
the effect of the active form of vitamin D, 
1,25-dihydroxyvitamin D (1,25(OH)2D) on inhibiting 
metastasis of breast cancer cells in an in vitro model 
of the breast to bone metastasis (rMET) (Wilmanski 
et al., 2016). However, the molecular mechanisms for 
1,25(OH)2D-mediated inhibition of metastasis are 
unknown. Therefore, further studies are needed to 
investigate the effect and mechanisms through which 
vitamin D inhibits breast cancer metastasis.
 
MMP activity is important to the first steps of metas-
tasis to evade the primary site; however, the role of 
MMPs in 1,25(OH)2D-mediated inhibition of metas-
tasis is unknown. Thus, the focus of this project is 
to investigate the role of 1,25(OH)2D in altering the 
mRNA expression of MMPs to inhibit the invasion 
and migration of breast cancer cells. 
METHODS
Cell Culture 
In this study, MCF10CA1a cells were utilized. These 
cells are mammary epithelial cells that represent 
the metastatic stage of cancer progression with the 
potential to invade distant secondary organs. MCF-
10CA1a cells were given as a gift from Dr. Julia 
Kirshner (Purdue University). For these experiments, 
cells were cultured in DMEM/F12, 1:1 supplemented 
with 5% horse serum, 100-units/ml Penicillin, and 
100-ug/mL streptomycin. Cells were treated with 
vehicle (ethanol) or 1,25(OH)2D (10 nm) (BIOMOL 
International) and delivered in 100% ethanol with a 
final ethanol concentration of <1%.The media was 
changed every 24 hours for the treatment period 
(Wilmanski et al., 2017). 
Scratch Wound Healing Assay
MCF10CA1a cells were plated in 6 well plates with 
90% confluence and scratched with a 200 ul pipette 
tip. After 48 hours, the MCF10CA1a cells were 
treated with vehicle or 1,25(OH)2D (10 nM). The new 
media containing 0.5% serum was added containing 
vehicle of 1,25(OH)2D, and images of wound closure 
were taken at time 0 and 24 hours. The results were 
quantified through TScratch.
Real-Time Quantitative PCR 
RNA was isolated with TriReagent. Reverse tran-
scription of total RNA was performed using MMLV 
reverse transcriptase, and real-time quantitative PCR 
was performed using the Brilliant II SYBR Green 
QPCR Master Mix. The mRNA expression was nor-
malized to 18S expression (Wilmanski et al., 2017). 
















Table 1. Primer sequences for MMPs.
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Impact of 1,25(OH)2D on  
Migration of MCF10CA1a
The role of 1,25(OH)2D in the migration or movement 
of metastatic cells (MCF10CA1a cells) is important 
to understand in order to determine how metastasis 
is inhibited. Therefore, due to the important role of 
migration in metastasis, the effect of 1,25(OH)2D on 
migration of MCF10CA1a cells was examined by a 
wound healing assay. As shown in Figure 1, pretreat-
ment of cells with 1,25(OH)2D for 48 hours decreased 
cell migration by 44%±9.6 relative to vehicle. The 
respective images can be seen in Figure 2. 
Impact of 1,25(OH)2D on MMP mRNA Expression 
The impact of 1,25(OH)2D treatment on the mRNA 
abundance of a variety of MMPs was investigated 
through real-time quantitative PCR. MMP1, MMP3, 
MMP9, and MMP13 mRNA levels were undetect-
able in MCF10CA1a cells. However, MMP2 mRNA 
expression levels were detectable. MMP2 mRNA 
abundance was significantly downregulated after  
48 hours and 5 days of 1,25(OH)2D treatment. Treat-
ment with 1,25(OH)2D (10 nM) reduced the expres-
sion of MMP2 by 32% ± 10 and 35% ± 7  at 2 and 5 
days, respectively, as seen in Figure 3. 
line, with a 20% reduction in cell viability in the 
lower bone matrix. It is noteworthy to emphasize that 
there was no 1,25(OH)2D in the bone cell conditioned 
media, and thus, the altered phenotype and survival 
are due to the treatment in the upper well prior to 
movement into the bottom well. Therefore, the ef-
fects on metastasis to the bone are due, at least in 
part, to the treatment of the cells prior to and during 
invasion and migration from the upper well. 
 
The 
Figure 1. 1,25(OH)2D inhibits migration of MCF10CA1a 
cells. MCF10CA1a cells were treated with vehicle or 
1,25(OH)2D (10nM) for 48 hours, after which each well 
was scratched with a 200ul pipette tip. New media 
containing 0.5% serum was added containing vehicle 
or 1,25(OH)2D, and wound closure was monitored for 40 
hours. *Indicates p-value < 0.05 relative to vehicle.
Figure 2. Representative images of MCF10CA1a breast 
epithelial cells from wound healing assay.






   
   
   
   
   
   
   
   
   
   
   
   
   




Figure 3. 1,25(OH)2D decreases mRNA expression  
of MMP2 in MCF10CA1a cells. MCF10CA1a cells were  
treated with vehicle or 1,25(OH)2D (10nM) for 48 
hours and 5 days, after which mRNA was isolated and 
expression was quantified using qRT-PCR. *Indicates  
p-value < 0.05 relative to vehicle.
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downregulating MMP2 expression. In addition, the 
downregulation of MMP2 may play a role in inhibit-
ing the migration of metastatic breast cancer cells. 
 
Vitamin D is a food component and is synthesized by 
human bodies. Thus, it is a safe component to recom-
mend for preventing metastasis. If the mechanisms 
of how vitamin D inhibits metastasis are determined, 
strategies can be developed to recommend specific 
intakes of the vitamin and may be targeted to specific 
populations to reduce the development of metasta-
sis. Since breast cancer metastasis greatly reduces 
the survivability of the cancer, the impact of these 
studies, when translated to the clinic and general 
population, may have a significant impact to reduce 
mortality associated with breast cancer. 
FURTHER STUDIES 
Our preliminary studies have shown that 1,25(OH)2D 
inhibits the migratory capability of MCF10CA1a 
cells using a wound healing assay. To further explore 
the impact of 1,25(OH)2D, additional wound healing 
assays with other cell lines such as the MDA-MB-231 
and 4T1 are necessary to ensure the effect is not 
specific to one cell line. 
 
In addition, it is important to determine if the 
downregulation of MMP2 by 1,25(OH)2D treatment 
plays a role in the inhibition of migration. To test 
this, inhibitors or activators of MMP2 activity can 
be used in the presence of vehicle or 1,25(OH)2D and 
migration assessed. In particular, MMP2 targeting 
siRNA to knockdown MMP2 expression or over-
expression of MMP2 in metastatic breast epithelial 
cells can be utilized. The MMP2 knockdown is 
expected to significantly inhibit both migration and 
invasion of metastatic breast epithelial cells, with 
1,25(OH)2D having no further effect on cell invasion. 
Similarly, we expect that a constitutive increase in 
MMP2 activity will significantly reduce or eliminate 
the 1,25(OH)2D inhibition of migration of metastatic 
breast epithelial cells.
 
Because of the important role of MMP2 in invasion, 
the impact of 1,25(OH)2D on invasive capability in the 
same breast epithelial metastatic cells (MCF10CA1a, 
MDA MB 231, and 4T1) also can be investigated. The 
invasion assay utilizes FluoroBlok matrigel coated 
transwell inserts with 8µm pore membrane. This cell 
culture system allows for quick invasive cell quantifi-
cation using Calcein AM and subsequent fluorescence 
quantification. Fluorescently labeled cells present 
in the top chamber of the insert are shielded from 
bottom-reading fluorescence plate readers and micro-
scopes by the FluoroBlok membrane.
DISCUSSION 
Epidemiological and animal studies support the 
hypothesis that vitamin D may inhibit breast cancer  
metastasis in humans, but the mechanism remains 
unknown. There are a number of studies in humans 
that show that vitamin D status is associated 
with reduced risk for metastasis including breast 
cancer (Ren et al., 2012; Hauser, Walsh, Shrotriya, 
& Karafa, 2014; Neuhouser et al., 2008; Mohr, 
Gorham, Kim, Hofflich, & Garland, 2014). Further, 
perfusion with the circulating metabolite of 
vitamin D, 25-hydroxyvitamin D (25(OH)D), in an 
MMTV-PyMT mouse model of metastatic breast 
cancer increased levels of the bioactive vitamin D 
metabolite, 1,25(OH)2D in the tumor, showing that 
increasing vitamin D status increases the local level 
of the active form of the vitamin in the tissue, In 
addition, tumor appearance was delayed, and lung 
metastasis decreased in this study (Rossdeutscher 
et al., 2014). In addition to studies in vivo, studies 
in cell models also support the hypothesis that 
1,25(OH)2D or its analogues inhibit metastasis, 
including invasion through matrigel and migration 
of MCF-7 and MCF10DCIS cells, and changes 
in expression of markers of metastatic capability. 
Therefore, evidence exist that 1,25(OH)2D inhibits 
invasive and migratory capability of breast cancer 
cells in vitro and the metastasis of breast cancer 
cells in vivo. Despite illustrating this beneficial 
effect, the mechanistic basis for the inhibitory 
action of vitamin D on breast cancer metastasis 
remains poorly understood. It is critical to 
understand this mechanism to appropriately design 
clinical trials with well-defined and measurable 
outcomes, and to determine when and to whom 
interventions should be targeted. 
 
Previous studies have shown the matrix metallopro-
teinase family to have a role in cancer and tumor  
metastasis. Of the 26 MMPs, MMP1, 2, 7, 9, 11, 13, 
and 14, along with the tissue inhibitors of MMPs, 
were quantified in invasive ducal breast tumors. 
MMP2 and MMP9 also have been examined as 
prognostic biomarkers in breast cancer (Radisky 
& Radisky, 2015). Thus, one mechanism by which 
1,25(OH)2D may inhibit metastasis is through down-
regulation of the expression of MMPs; however, this 
has not been examined. 
 
The results of the current study demonstrate that 
1,25(OH)2D can downregulate the mRNA levels of 
MMP2, which may lead to a potential change in the 
protein expression. Therefore, vitamin D through its 
active form, 1,25(OH)2D, may be an effective agent 
in inhibiting invasion of breast cancer cells through 
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